Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler's 36th Annual Healthcare Conference:
加利福尼亞州門洛公園，2024年11月19日（GLOBE NEWSWIRE）——生物技術公司Oruka Therapeutics, Inc.（「Oruka」）（納斯達克股票代碼：ORKA）是一家開發旨在爲包括斑塊狀牛皮癬在內的慢性皮膚病治療設定新標準的生物製劑的生物技術公司，今天宣佈參加派珀·桑德勒的第36屆年度醫療保健會議並在爐邊談話：
Date: Tuesday, December 3rd, 2024
Time: 3:00PM ET
日期：2024 年 12 月 3 日星期二
時間：美國東部時間下午 3:00
About Oruka Therapeutics
關於 Oruka 療法
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka Therapeutics正在開發新的生物製劑，旨在爲慢性皮膚病的治療設定新的標準。Oruka的使命是通過實現較高的完全清除率，每年少給藥一兩次，爲患有斑塊狀牛皮癬等慢性皮膚病的患者提供儘可能大的擺脫病情的機會。Oruka正在推進由Paragon Therapeutics設計的潛在同類最佳抗體的專有產品組合，針對斑塊狀銀屑病和其他皮膚病和炎症性疾病的核心機制。欲了解更多信息，請在領英上訪問並關注 Oruka。
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投資者聯繫人：
艾倫·拉達
(650) -606-7911
alan.lada@orukatx.com
